Why Regeneron Is Falling And Why You Should Avoid It

Regeneron Pharmaceuticals (REGN) has been in a persistent downtrend for over 280 days. The stock is currently in the 10th Phase of its 18-Phase Adhishthana Cycle, our proprietary cyclical framework. Let’s break down why this fall isn’t just technical noise and what the Adhishthana Principles reveal about what lies ahead.

Read the full article on Benzinga for deeper insights into the Adhishthana Cycle, the stock’s recent trajectory, and expert commentary.